Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor gene

Molecular Psychiatry

Volumn 9, Issue 3, 2004, Pages 293-298

  Kishida, I ^a   Kawanishi, C ^a   Furuno, T ^a   Kato, D ^a   Ishigami, T ^a   Kosaka, K ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

141C Ins Del; Dopamine D2 receptor (DRD 2); Genetic polymorphism; Neuroleptic malignant syndrome; Ser311Cys; TaqI A

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NEUROLEPTIC MALIGNANT SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA;

AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CONFIDENCE INTERVALS; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; JAPAN; LEUKOCYTES; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, DOPAMINE D2; SEQUENCE DELETION;

EID: 1942469942     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001422     Document Type: Article

References (27)

1. Deuschl G, Oepen G, Hermle L. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 1987; 20: 168-170.
2. Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991; 158: 850-853.
3. 2 dopamine receptor missense variants. J Biol Chem 1996; 271: 26013-26017.
4. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-582.
5. Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296.
6. Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, Syvälahti EKG et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 256-260.
7. 2 receptor gene. Am J Psychiatry 2001; 158: 802-804.
8. 2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11: 545-550.
9. 2 gene. Psychopharmacology 2000; 149: 246-250.
10. 2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001; 158: 1714-1716.
11. 2 receptor gene. Psychiatric Genet 2003; 13: 55-57.
12. Pope GH, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143: 1227-1233.
13. 2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989; 45: 778-785.
14. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 774-778.
15. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, Hamaguchi H et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 1994; 343: 703-704.
16. Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence orally administered neuroleptics. In: Dose Equivalence of Psychotropic Drugs. Seiwa Shoten: Tokyo, 1999; 11-60, (in Japanese).
17. American Psychiatry Association. Practice guideline for the treatment of patients with schizophrenia. III. Treatment principles and alternatives. Am J Psychiatry 1997; 154: 7-34.
18. Schneider S, Roessli D, Excoffier L. ARLEQUIN: a Software for Population Genetic Data Analysis. University of Geneva: Geneva, 2000.
19. Nishijima K, Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry 1990; 27: 280-288.
20. 123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Movement Disord 1996; 11: 726-728.
21. Ishiguro H, Arinami T, Saito T, Akazawa S, Enomoto M, Mitushio H et al. Association study between the -141C Ins/Del and TaqI A polymorphisms of the dopamine D2 receptor gene and alcoholism. Alc Clin Exp Res 1998; 22: 845-848.
22. Katsuragi S, Kiyota A, Tsutsumi T, Isogawa K, Nagayama H, Arinami T et al. Lack of association between a polymorphism in the promoter region of the dopamine D2 receptor and personality traits. Psychiatry Res 2001; 105: 123-127.
23. 2 receptor gene promoter and schizophrenia. Psychiatry Res 1998; 81: 117-123.
24. 2 receptor density in vivo. Pharmacogenetics 1999; 9: 505-509.
25. 3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet 2003; 117B: 57-60.
26. 2A receptor genes. Am J Psychiatry 1998; 155: 1275-1277.
27. Kawanishi C, Furuno T, Onishi H, Sugiyama N, Suzuki K, Matsumura T et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatric Genet 2000; 10: 145-147.